ClinicalTrials.gg
Sign In
Not yet recruitingNCT07749573Updated Aug 6, 2026

The Effect of Chewing Gum on Dizziness in Patients Diagnosed With Posterior Canal Benign Paroxysmal Positional Vertigo in the Emergency Department

An interventional study of Dimenhydrinate and Sugar-Free Mint-Flavored Chewing Gum in Vertigo Benign Positional and Dizziness, sponsored by Ankara Ataturk Sanatorium Training and Research Hospital. Not yet recruiting at 1 site in Turkey (Türkiye). Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-08-06.

Sponsored by Ankara Ataturk Sanatorium Training and Research Hospital · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
88
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

Dizziness is a common reason for emergency department visits. Posterior canal benign paroxysmal positional vertigo (BPPV) is one of the most frequent causes of peripheral vertigo. Intravenous dimenhydrinate is among the standard treatments administered in the emergency setting; however, this and similar drug classes may cause sedation and delay central compensation.

This study tests the hypothesis that chewing gum may modulate the vestibular system via trigeminal and cervical neuromuscular pathways, thereby reducing dizziness and nausea symptoms. Patients diagnosed with posterior canal BPPV who are started on intravenous dimenhydrinate will be randomly assigned to two groups: the intervention group will chew sugar-free mint-flavored gum for 20 minutes in addition to standard treatment, while the control group will receive standard treatment only. Dizziness and nausea severity will be assessed using VAS at baseline, 20 minutes, and 60 minutes.

02

Conditions studied

  • Vertigo Benign Positional
  • Dizziness
03

In context

Benign Paroxysmal Positional Vertigo

75 studies on the registry are indexed under Benign Paroxysmal Positional Vertigo; 15 are open to participants now.

This study's planned enrollment of 88 is above the median of 78 across 62 interventional studies indexed under Benign Paroxysmal Positional Vertigo.

Browse Benign Paroxysmal Positional Vertigo studies →

Lead sponsor

Ankara Ataturk Sanatorium Training and Research Hospital is the lead sponsor of 38 studies on the registry; 15 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged 18-65 years
  • Duration of dizziness complaint less than 24 hours
  • Posterior canal BPPV diagnosis confirmed by the emergency physician via the Dix-Hallpike test
  • Intravenous administration of 50 mg dimenhydrinate in 100 cc 0.9% NaCl initiated by the responsible emergency physician
  • Symptomatic dizziness with VAS ≥ 4
  • Alert, cooperative, and able to chew gum
  • Willingness to participate and provision of written

Exclusion criteria

Exclusion Criteria:

  • Findings suggestive of central vertigo (vertical nystagmus, diplopia, ataxia, hemiparesis, focal neurological deficit, etc.)
  • Pregnancy
  • Known gum intolerance, history of allergy to gum or its , temporomandibular joint dysfunction, significant tooth loss, use of dentures or removable prosthetics that would prevent chewing
  • Altered level of consciousness
  • Central pathology detected on investigations performed during the visit
  • Hemodynamic and/or respiratory instability
  • Diagnosis other than posterior canal BPPV as the cause of vertigo
  • Treatment other than pharmacological therapy planned or already administered by the responsible emergency physician
  • Active vomiting at the time of enrollment
  • Severe dizziness with VAS ≥ 8 (excluded due to high likelihood of requiring additional treatment, risk of protocol deviation, and safety concerns regarding gum chewing)
  • Patients who initially consented but subsequently wish to withdraw from the study
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colours or preservatives.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
88 participants (estimated)

Study arms

  • Active comparator
    Control Group

    Patients receive only the standard treatment initiated by the responsible emergency physician: 50 mg dimenhydrinate in 100 cc 0.9% NaCl administered intravenously

    Drug: Dimenhydrinate

  • Experimental
    Intervention Group

    In addition to standard treatment (50 mg dimenhydrinate in 100 cc 0.9% NaCl IV), patients receive sugar-free mint-flavored chewing gum simultaneously with the start of treatment and chew it under observation for 20 minutes.

    Drug: Dimenhydrinate · Behavioral: Sugar-Free Mint-Flavored Chewing Gum

Interventions

  • DrugDimenhydrinate

    Dimenhydrinate 50 mg diluted in 100 mL of 0.9% sodium chloride administered intravenously as standard treatment for posterior canal benign paroxysmal positional vertigo in the emergency department.

  • BehavioralSugar-Free Mint-Flavored Chewing Gum

    Participants chew one piece of sugar-free mint-flavored chewing gum under observation for 20 minutes, starting simultaneously with standard intravenous treatment.

06

What researchers measure

Primary outcomes

  1. Change in dizziness Visual Analog Scale score from baseline to 20 minutes

    The primary outcome is the change in dizziness severity measured using a 10-cm Visual Analog Scale, ranging from 0 (no dizziness) to 10 (worst imaginable dizziness), with higher scores indicating greater dizziness severity, between baseline and 20 minutes after treatment initiation.

    Time frame: Baseline and 20 minutes after treatment initiation

Secondary outcomes

  1. Nausea Visual Analog Scale score at 20 minutes

    Nausea severity will be assessed 20 minutes after treatment initiation using a 10-cm Visual Analog Scale, ranging from 0 (no nausea) to 10 (worst imaginable nausea), with higher scores indicating greater nausea severity.

    Time frame: 20 minutes after treatment initiation

07

Study locations

1 site
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Sep 2026; primary completion for Sep 2027, 12 months later.

Of 38 non-industry interventional studies with no phase under Benign Paroxysmal Positional Vertigo, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 26. This study's planned 12 months is below that.

Counting every sponsor, half of 39 studies reached it within 16 months; a quarter within 8 and three quarters within 26.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 23, 2026
First posted
Aug 6, 2026
StartEst.
Sep 1, 2026
Primary completionEst.
Sep 1, 2027
CompletionEst.
Dec 1, 2027
Last update
Aug 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07749573
Lead sponsor
Ankara Ataturk Sanatorium Training and Research Hospital
Responsible party
Şeref Kerem Çorbacıoğlu (Profesor, Ankara Ataturk Sanatorium Training and Research Hospital) — Principal investigator
First posted
Aug 6, 2026
Start date
Sep 1, 2026 (estimated)
Primary completion
Sep 1, 2027 (estimated)
Completion
Dec 1, 2027 (estimated)
Last update
Aug 6, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Benign Paroxysmal Positional Vertigo →

Other studies from this sponsor

Ankara Ataturk Sanatorium Training and Research Hospital

Start the discussion